8-K current report · filed Aug 5, 2026

Mirum Pharmaceuticals, Inc. (MIRM) 8-K Current Report: August 5, 2026

Item 2.02Item EX-99.1MIRM overview

Short answer

Mirum Pharmaceuticals, Inc. (MIRM) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results and corporate update announced for quarter ended June 30, 2026.

Mirum Pharmaceuticals, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 financial results and corporate update announced for quarter ended June 30, 2026
  • Full results and management commentary available in Exhibit 99.1
  • Disclosure furnished under Regulation FD, generally not subject to Exchange Act Section 18 liability

Item EX-99.1 · Exhibit EX-99.1

  • Q2 net product sales $176.2M, up from $127.8M, led by LIVMARLI sales $128.7M, up 46% year over year
  • 2026 sales guidance raised to $680M-$700M, signaling stronger commercial momentum and increased revenue visibility
  • Volixibat PSC NDA target shifted to H1 2027 after FDA recommended a Phase 3 study, extending development timeline and potential launch
  • Zilurgisertib FOP NDA under Priority Review, with FDA action date September 26, 2026, creating a near-term regulatory catalyst
  • Cash, equivalents, and investments $561.3M, while Q2 net loss widened to $67.2M amid $218.8M operating expenses and pipeline investment

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Mirum Pharmaceuticals, Inc. 8-K filings

Get the next MIRM 8-K as it lands

Follow MIRM for push alerts, or ask the research agent what this filing means.